Helicobacter pylori -specific protection against inflammatory bowel disease requires the NLRP3 inflammasome and IL-18

Inflammatory Bowel Diseases

Volumn 21, Issue 4, 2015, Pages 854-861

  Engler, Daniela B ^a   Leonardi, Irina ^b   Hartung, Mara L ^a   Kyburz, Andreas ^a   Spath, Sabine ^a   Becher, Burkhard ^a   Rogler, Gerhard ^b   Müller, Anne ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

autoimmunity; chronic intestinal inflammation; inflammasome activation; microbial immunomodulation; mucus production

Indexed keywords

CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; DEXTRAN SULFATE; INTERLEUKIN 18; MUC2 PROTEIN, MOUSE; MUCIN 2;

ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COLITIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETICS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IMMUNOLOGY; MALE; METABOLISM; MICROBIOLOGY; MOUSE; NONOBESE DIABETIC MOUSE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSCRIPTION INITIATION; UPREGULATION;

ANIMALS; CARRIER PROTEINS; COLITIS; DEXTRAN SULFATE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; INTERLEUKIN-18; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MUCIN-2; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84928172036     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000318     Document Type: Article

References (37)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
2. Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis. 2007;44:256-262.
3. Rogler G. Top-down or step-up treatment in Crohn's disease?. Dig Dis. 2013;31:83-90.
4. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013;29:397-404.
5. Blum AM, Hang L, Setiawan T, et al. Heligmosomoides polygyrus bakeri induces tolerogenic dendritic cells that block colitis and prevent antigenspecific gut T cell responses. J Immunol. 2012;189:2512-2520.
6. Hang L, Setiawan T, Blum AM, et al. Heligmosomoides polygyrus infection can inhibit colitis through direct interaction with innate immunity. J Immunol. 2010;185:3184-3189.
7. Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy for active ulcerative colitis. A randomized controlled trial. Gastroenterology. 2005;128:825-832.
8. Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy in Crohn's disease. Gut. 2005;54:87-90.
9. Dylag K, Hubalewska-Mazgaj M, Surmiak M, et al. Probiotics in the mechanism of protection against gut inflammation and therapy of gastrointestinal disorders. Curr Pharm Des. 2014;20:1149-1155.
10. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311-1315.
11. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127-1131.
12. Huang JQ, Zheng GF, Sumanac K, et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2003; 125:1636-1644.
13. Luther J, Dave M, Higgins PD, et al. Association between Helicobacter pylori infection and inflammatory bowel disease. A meta-analysis and systematic review of the literature. Inflamm Bowel Dis. 2010;16:1077-1084.
14. Wang Q, Yu C, Sun Y. The association between asthma and Helicobacter pylori. A meta-analysis. Helicobacter. 2013;18:41-53.
15. Sonnenberg A, Genta RM. Low prevalence of Helicobacter pylori infection among patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:469-476.
16. Arnold IC, Dehzad N, Reuter S, et al. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest. 2011;121:3088-3093.
17. Oertli M, Sundquist M, Hitzler I, et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest. 2012;122:1082-1096.
18. Engler DB, Reuter S, van Wijck Y, et al. Effective treatment of allergic airway inflammation with Helicobacter pylori immunomodulators requires BATF3-dependent dendritic cells and IL-10. Proc Natl Acad Sci U S A. 2014;111:11810-11815.
19. Oertli M, Noben M, Engler DB, et al. Helicobacter pylori g-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci U S A. 2013;110:3047-3052.
20. Arnold IC, Lee JY, Amieva MR, et al. Tolerance rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia. Gastroenterology. 2011;140:199-209.
21. Asseman C, Mauze S, Leach MW, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190:995-1004.
22. Becker C, Fantini MC, Neurath MF. High resolution colonoscopy in live mice. Nat Protoc. 2006;1:2900-2904.
23. Codarri L, Gyulveszi G, Tosevski V, et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol. 2011; 12:560-567.
24. Efrat S, Serreze D, Svetlanov A, et al. Adenovirus early region 3(E3) immunomodulatory genes decrease the incidence of autoimmune diabetes in NOD mice. Diabetes. 2001;50:980-984.
25. Sayi A, Kohler E, Hitzler I, et al. The CD4+ T cell-mediated IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk. J Immunol. 2009;182:7085-7101.
26. Powrie F, Leach MW, Mauze S, et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993;5:1461-1471.
27. Allen A, Hutton DA, Pearson JP. The MUC2 gene product. A human intestinal mucin. Int J Biochem Cell Biol. 1998;30:797-801.
28. Yamamoto H, Bai YQ, Yuasa Y. Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophys Res Commun. 2003;300:813-818.
29. Jonk LJ, Itoh S, Heldin CH, et al. Identification and functional characterization of a smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem. 1998;273:21145-21152.
30. Bollrath J, Powrie FM. Controlling the frontier: regulatory T-cells and intestinal homeostasis. Semin Immunol. 2013;25:352-357.
31. Hitzler I, Sayi A, Kohler E, et al. Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1beta and IL-18. J Immunol. 2012;188: 3594-3602.
32. Kim DJ, Park JH, Franchi L, et al. The Cag pathogenicity island and interaction between TLR2/NOD2 and NLRP3 regulate IL-1beta production in Helicobacter pylori-infected dendritic cells. Eur J Immunol. 2013.
33. Wang Y, Tong J, Chang B, et al. Genetic polymorphisms in the IL-18 gene and ulcerative colitis risk. A meta-analysis. DNA Cell Biol. 2014;33: 438-447.
34. Higgins PD, Johnson LA, Luther J, et al. Prior Helicobacter pylori infection ameliorates Salmonella typhimurium-induced colitis: mucosal crosstalk between stomach and distal intestine. Inflamm Bowel Dis. 2011;17:1398-1408.
35. Luther J, Owyang SY, Takeuchi T, et al. Helicobacter pylori DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis. Gut. 2011;60:1479-1486.
36. Semper RP, Mejias-Luque R, Gross C, et al. Helicobacter pylori-Induced IL-1beta secretion in innate immune cells is Regulated by the NLRP3 inflammasome and requires the Cag pathogenicity island. J Immunol. 2014;193:3566-3576.
37. Wlodarska M, Thaiss CA, Nowarski R, et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell. 2014;156:1045-1059.